about
Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer.Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysisPhase I Dose-Escalation Study of Docetaxel, Cisplatin, and 5-Fluorouracil Combination Chemotherapy in Patients With Advanced Esophageal CarcinomaForkhead box transcription factor 1 expression in gastric cancer: FOXM1 is a poor prognostic factor and mediates resistance to docetaxel
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Docetaxel for gastric and esophageal carcinomas.
@ast
Docetaxel for gastric and esophageal carcinomas.
@en
Docetaxel for gastric and esophageal carcinomas.
@nl
type
label
Docetaxel for gastric and esophageal carcinomas.
@ast
Docetaxel for gastric and esophageal carcinomas.
@en
Docetaxel for gastric and esophageal carcinomas.
@nl
prefLabel
Docetaxel for gastric and esophageal carcinomas.
@ast
Docetaxel for gastric and esophageal carcinomas.
@en
Docetaxel for gastric and esophageal carcinomas.
@nl
P1433
P1476
Docetaxel for gastric and esophageal carcinomas.
@en
P2093
Jaffer A Ajani
P433
P577
2002-06-01T00:00:00Z